CSL (OTCMKTS:CSLLY) Cut to Strong Sell at Zacks Research

Zacks Research lowered shares of CSL (OTCMKTS:CSLLY) from a hold rating to a strong sell rating in a research note issued to investors on Monday morning,Zacks.com reports.

CSL Trading Down 0.6%

CSLLY stock opened at $66.66 on Monday. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. CSL has a 1 year low of $64.68 and a 1 year high of $101.44. The stock has a 50-day simple moving average of $78.36 and a 200-day simple moving average of $78.59.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.